Santen Pharmaceutical Co Ltd (4536) - Financial and Strategic SWOT Analysis Review

Region:Asia

Author(s):

Product Code:GDPH6375FSA

Download Sample Report download
Buy the Full ReportStarting from $125
Published on

July 2019

Total pages

52

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $125

About the Report

About the Report

Santen Pharmaceutical Co Ltd (4536)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Santen Pharmaceutical Co Ltd (Santen) focuses on the research, development, manufacture and marketing of pharmaceutical products and medical devices. Its product portfolio includes prescription ophthalmic products for bacterial conjunctivitis, glaucoma, dry eye, inflammation and others; OTC ophthalmic products; anti-allergy ophthalmic products; and medical devices such as intraocular lenses (IOLs) and others. Santen operates through group companies in Asia, Europe and the US. The company's R&D activities focus on the development of ophthalmic treatments. Santen is headquartered in Kita-ku, Osaka, Japan.

Santen Pharmaceutical Co Ltd Key Recent Developments

Jun 26,2019: OXB and Santen to develop gene therapy products for retinal disease

Jun 13,2019: Santen's commitment to ophthalmology underlined by strong preliminary data and symposia detailing the latest in glaucoma and dry eye disease management at SOE 2019

May 09,2019: Santen reports fiscal 2018 consolidated performance

Mar 06,2019: Santen announces selection and launch of its gene therapy drug research and development project for inherited ocular disease treatment for the cyclic innovation for clinical empowerment (CiCLE) program

Mar 06,2019: Santen announces selection and launch of its photo-crosslinking research and development project for pathologic myopia treatment for the cyclic innovation for clinical empowerment (CiCLE) program

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Products

Products

Santen Pharmaceutical Co Ltd, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Taisho Pharmaceutical Holdings Co Ltd

Senju Pharmaceutical Co Ltd

Mitsubishi Tanabe Pharma Corp

Hoya Corp

Daiichi Sankyo Co Ltd

Chugai Pharmaceutical Co Ltd

Astellas Pharma Inc

Aqumen Biopharmaceuticals

Alcon Japan Ltd

Table of Contents

Table of Contents

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

Santen Pharmaceutical Co Ltd-Key Facts

Santen Pharmaceutical Co Ltd-Key Employees

Santen Pharmaceutical Co Ltd-Major Products and Services

Santen Pharmaceutical Co Ltd-History

Santen Pharmaceutical Co Ltd-Company Statement

Santen Pharmaceutical Co Ltd-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2-Company Analysis

Company Overview

Santen Pharmaceutical Co Ltd-Business Description

Business Segment: Medical Devices

Overview

Performance

Business Segment: OTC Pharmaceuticals

Overview

Performance

Business Segment: Others

Performance

Business Segment: Prescription Pharmaceuticals

Overview

Performance

Geographical Segment: Asia

Performance

Geographical Segment: EMEA

Performance

Geographical Segment: Japan

Performance

Geographical Segment: US

Performance

R&D Overview

Santen Pharmaceutical Co Ltd-Corporate Strategy

Santen Pharmaceutical Co Ltd-SWOT Analysis

SWOT Analysis-Overview

Santen Pharmaceutical Co Ltd-Strengths

Santen Pharmaceutical Co Ltd-Weaknesses

Santen Pharmaceutical Co Ltd-Opportunities

Santen Pharmaceutical Co Ltd-Threats

Santen Pharmaceutical Co Ltd-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Santen Pharmaceutical Co Ltd, Recent Deals Summary

Section 5-Company's Recent Developments

Jun 26, 2019: OXB and Santen to develop gene therapy products for retinal disease

Jun 13, 2019: Santen's commitment to ophthalmology underlined by strong preliminary data and symposia detailing the latest in glaucoma and dry eye disease management at SOE 2019

May 09, 2019: Santen reports fiscal 2018 consolidated performance

Mar 06, 2019: Santen announces selection and launch of its gene therapy drug research and development project for inherited ocular disease treatment for the cyclic innovation for clinical empowerment (CiCLE) program

Mar 06, 2019: Santen announces selection and launch of its photo-crosslinking research and development project for pathologic myopia treatment for the cyclic innovation for clinical empowerment (CiCLE) program

Nov 07, 2018: Santen reports consolidated results for Q2 fiscal 2018

Sep 12, 2018: Santen Pharmaceutical announce personnel changes of representative Director of the Board

Jul 17, 2018: Santen Donates to Japan Flood and Landslide Relief Efforts

Jun 04, 2018: Santen Announces Medium-Term Plan (MTP2020)

May 09, 2018: Santen Reports Fiscal 2017 Consolidated Performance

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List of Figure

List of Figures

Santen Pharmaceutical Co Ltd, Performance Chart (2015-2019)

Santen Pharmaceutical Co Ltd, Ratio Charts

Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List of Table

List of Tables

Santen Pharmaceutical Co Ltd, Key Facts

Santen Pharmaceutical Co Ltd, Key Employees

Santen Pharmaceutical Co Ltd, Major Products and Services

Santen Pharmaceutical Co Ltd, History

Santen Pharmaceutical Co Ltd, Other Locations

Santen Pharmaceutical Co Ltd, Subsidiaries

Santen Pharmaceutical Co Ltd, Key Competitors

Santen Pharmaceutical Co Ltd, Ratios based on current share price

Santen Pharmaceutical Co Ltd, Annual Ratios

Santen Pharmaceutical Co Ltd, Annual Ratios (Cont...1)

Santen Pharmaceutical Co Ltd, Annual Ratios (Cont...2)

Santen Pharmaceutical Co Ltd, Interim Ratios

Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Santen Pharmaceutical Co Ltd, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022